Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.
Record details
- ISBN: 152473165X
- ISBN: 9781524731656 (hardback)
- ISBN: 9781524731656 : HRD
- ISBN: 152473165X : HRD
- ISBN: 9781524731656 (hardcover)
- ISBN: 152473165X (hardcover)
- Physical Description: x, 339 pages ; 25 cm
- Edition: First edition.
- Publisher: New York : Alfred A. Knopf, 2018.
- Copyright: ©2018
Content descriptions
Bibliography, etc. Note: | Includes bibliographical references and index. |
Formatted Contents Note: | A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\Day -- Going live -- Unicorn -- The grandson -- Fame -- The Hippocratic Oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue. |
Summary, etc.: | In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley. |
Search for related items by subject
Available copies
- 43 of 43 copies available at Bibliomation.
- 1 of 1 copy available at Howard Whittemore Library - Naugatuck. (Show preferred library)
Holds
- 0 current holds with 43 total copies.
Other Formats and Editions
Show Only Available Copies
Location | Call Number / Copy Notes | Barcode | Shelving Location | Status | Due Date |
---|---|---|---|---|---|
Howard Whittemore Library - Naugatuck | 338.76 CAR (Text) | 34027141430374 | Adult Nonfiction | Available | - |
Ansonia Public Library | 338.7 CAR (Text) | 34045138752360 | Adult Nonfiction | Available | - |
Beekley Community Library - New Hartford | 338.7 CARREYROU, J. (Text) | 32544072514168 | Adult Nonfiction | Available | - |
Bethel Public Library | 338.7 CAR (Text) | 34030142370102 | Adult Nonfiction | Available | - |
Brookfield Library | 338.7681/CARREYROU (Text) | 34029145292917 | Adult Nonfiction | Available | - |
Burnham Library - Bridgewater | 338.7 CARREYROU (Text) | 36937000621939 | Adult Nonfiction | Available | - |
C.H. Booth Library - Newtown | 338.7 CAR (Text) | 34014142310417 | Adult Nonfiction | Available | - |
Canterbury Public Library | 338.76 CARREYROU (Text) | 33190000430413 | Adult Nonfiction | Available | - |
David M. Hunt Library - Falls Village | 338.7 Car (Text) | 33180141806480 | Adult Nonfiction | Available | - |
Derby Neck Library | 338.76 CAR (Text) | 34046145336650 | Adult Nonfiction | Available | - |
Electronic resources
Bad Blood : Secrets and Lies in a Silicon Valley Startup
Click an element below to view details:
Summary
Bad Blood : Secrets and Lies in a Silicon Valley Startup
NATIONAL BESTSELLER * The gripping story of Elizabeth Holmes and Theranos--one of the biggest corporate frauds in history--a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword. "Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection." -- The New York Times Book Review In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.5 billion. There was just one problem: The technology didn't work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings--from journalists to their own employees.